Topics

Drinking Water Wastewater Treatment Smart Water Asset Management Water Utility Management

Resources

Global Thought Leaders Events Magazine WaterWorldTV White Papers Webcasts

User Tools

Subscribe Advertise About Us Contact Us Privacy Policy Terms & Conditions

Press Releases

https://www.facebook.com/waterworldmag

https://www.linkedin.com/showcase/waterworld-magazine/about/

https://twitter.com/WaterWorld

Recent Quotes

My Watchlist

Indicators

WaterWorld Market Index

Markets:

Overview

News

Currencies

International

Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

4.310 -0.240 (-5.27%)

Streaming Delayed Price Updated: 12:23 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million

March 28, 2023

From SciSparc Ltd

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

March 27, 2023

Welcome back and get ready for another day of trading with a breakdown of the biggest pre-market stock movers for Monday!

Via InvestorPlace

SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

March 10, 2023

From SciSparc Ltd

Via GlobeNewswire

Update: SciSparc To Spin Off Pharmaceutical Activities Into New Subsidiary ↗

March 01, 2023

The jury is out on how well SciSparc will do in executing its restructuring plan, but the company has no other choice.

Via Talk Markets

SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

March 09, 2023

From SciSparc Ltd

Via GlobeNewswire

SciSparc Completes Production Of Its Dronabinol-Based Drug Candidate For Its Clinical Trial On Tourette Syndrome ↗

March 06, 2023

SciSparc Ltd. (NASDAQ: SPRC) has successfully manufactured clinical batches of its drug candidate SCI-110 to be used in its upcoming multinational, multicenter, phase IIb trial for Tourette syndrome.

Via Benzinga

SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome

March 06, 2023

From SciSparc Ltd

Via GlobeNewswire

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗

February 27, 2023

Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...

Via Benzinga

SciSparc's CBD-Based Drug One Step Closer To Clinical Trial On Children With Autism Spectrum Disorder ↗

February 27, 2023

SciSparc Ltd. (NASDAQ: SPRC) has signed an agreement with Israel's manufacturer and distributor of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., Israel (TASE:TKUN), to supply...

Via Benzinga

SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder

February 27, 2023

From SciSparc Ltd

Via GlobeNewswire

Jeffs' Brands To Acquire A 49% Interest In A Company That Owns A Top Seller Brand On Amazon For $2.5M ↗

February 23, 2023

Jeffs' Brands Ltd (NASDAQ: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, has entered into a definitive agreement with SciSparc Ltd.

Via Benzinga

Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million

February 23, 2023

From Jeffs' Brands Ltd

Via GlobeNewswire

SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million

February 23, 2023

From SciSparc Ltd

Via GlobeNewswire

SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds ↗

February 22, 2023

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its...

Via Benzinga

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

February 22, 2023

Clearmind Medicine submitted patent applications to protect the novel compounds

From SciSparc Ltd

Via GlobeNewswire

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

February 22, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 21, 2023

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

Via Benzinga

Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket ↗

February 21, 2023

Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday.

Via Benzinga

Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 17, 2023

Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program.

Via Benzinga

Why SciSparc Shares Are Moving During Friday's Session ↗

February 17, 2023

SciSparc Ltd (NASDAQ: SPRC) shares are trading higher by 8.08% to $0.98 Friday morning, though off the session high of $1.33, after the company announced its MitoCareX Bio joint venture achieved...

Via Benzinga

Why Is SciSparc (SPRC) Stock Up 14% Today? ↗

February 17, 2023

SciSparc (SPRC) stock is taking off on Friday as investors react to an update on its drug development joint venture MitoCareX Bio.

Via InvestorPlace

SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System

February 17, 2023

From SciSparc Ltd

Via GlobeNewswire

Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US ↗

February 15, 2023

Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications...

Via Benzinga

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US

February 15, 2023

From SciSparc Ltd

Via GlobeNewswire

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

February 15, 2023

From Clearmind Medicine Inc.

Via GlobeNewswire

Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 25, 2023

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products.

Via Benzinga

SciSparc Announces Corporate Restructuring plan

January 25, 2023

From SciSparc Ltd

Via GlobeNewswire

Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 23, 2023

Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its...

Via Benzinga

SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares

January 23, 2023

From SciSparc Ltd

Via GlobeNewswire

Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results ↗

January 18, 2023

Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical...

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

https://www.facebook.com/waterworldmag

https://www.linkedin.com/showcase/waterworld-magazine/about/

https://twitter.com/WaterWorld

Subscribe
About Us
Contact Us
Do Not Sell or Share
Privacy Policy
Terms & Conditions